Monocyte response to LPS after exposure to corticosteroids and chloroquine with implications for systemic lupus erythematosus

Scandinavian Journal of Immunology

Volumn 72, Issue 5, 2010, Pages 434-443

  Cepika, A M ^a,b   Bendelja, K ^b   Vergles, J M ^c   Malenica, B ^d   Kapitanovic, S ^e   Gagro, A ^a,b  

^a Croatia   (Croatia)

^b INSTITUTE OF IMMUNOLOGY   (Croatia)

^c University of Zagreb School of Medicine   (Croatia)

^d KBC Zagreb   (Croatia)

^e RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LEUKOCYTE CULTURE; MONOCYTE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADRENAL CORTEX HORMONES; ANTIRHEUMATIC AGENTS; CELLS, CULTURED; CHLOROQUINE; DEXAMETHASONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MONOCYTES; NF-KAPPA B; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77958084795     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2010.02450.x     Document Type: Article

References (54)

1. Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity 2005;38:473-85.
2. Palsson-McDermott EM, O'Neill LAJ. Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4. Immunology 2004;113:153-62.
3. Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol 2003;15:528-34.
4. Chapman RE, Munro S. Retrieval of TGN proteins from the cell surface requires endosomal acidification. EMBO J 1994;13:2305-12.
5. Ohkuma S, Poole B. Cytoplasmic vacuolation of mouse peritoneal macrophages and the uptake into lysosomes of weakly basic substances. J Cell Biol 1981;90:656-64.
6. Jang CH, Choi JH, Byun MS, Jue DM. Chloroquine inhibits production of TNF-alpha, IL-1beta and IL-6 from lipopolysaccharide-stimulated human monocytes/macrophages by different modes. Rheumatology (Oxford) 2006;45:703-10.
7. Jeong JY, Jue DM. Chloroquine inhibits processing of tumor necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophages. J Immunol 1997;158:4901-7.
8. Karres I, Kremer JP, Dietl I, Steckholzer U, Jochum M, Ertel W. Chloroquine inhibits proinflammatory cytokine release into human whole blood. Am J Physiol 1998;274:R1058-64.
9. Picot S, Peyron F, Donadille A, Vuillez JP, Barbe G, Ambroise-Thomas P. Chloroquine-induced inhibition of the production of TNF, but not of IL-6, is affected by disruption of iron metabolism. Immunology 1993;80:127-33.
10. Weber SM, Levitz SM. Chloroquine interferes with lipopolysaccharide-induced TNF-alpha gene expression by a nonlysosomotropic mechanism. J Immunol 2000;165:1534-40.
11. Weber SM, Chen JM, Levitz SM. Inhibition of mitogen-activated protein kinase signaling by chloroquine. J Immunol 2002;168:5303-9.
12. Brunetti M, Martelli N, Colasante A, Piantelli M, Musiani P, Aiello FB. Spontaneous and glucocorticoid-induced apoptosis in human mature T lymphocytes. Blood 1995;86:4199-205.
13. Ito K, Barnes PJ, Adcock IM. Glucocorticoid receptor recruitment of histone deacetylase 2 inhibits interleukin-1beta-induced histone H4 acetylation on lysines 8 and 12. Mol Cell Biol 2000;20:6891-903.
14. Hayashi R, Wada H, Ito K, Adcock IM. Effects of glucocorticoids on gene transcription. Eur J Pharmacol 2004;500:51-62.
15. Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J 2006;27:413-26.
16. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis.[see comment]. Science 1995;270:286-90.
17. Hornung V, Rothenfusser S, Britsch S etal. Quantitative expression of Toll-Like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 2002;168:4531-7.
18. Lee YH, Harley JB, Nath SK. Meta-analysis of TNF-alpha promoter -308 A/G polymorphism and SLE susceptibility. Eur J Hum Genet 2006;14:364-71.
19. Katsiari CG, Liossis SN, Souliotis VL, Dimopoulos AM, Manoussakis MN, Sfikakis PP. Aberrant expression of the costimulatory molecule CD40 ligand on monocytes from patients with systemic lupus erythematosus. Clin Immunol 2002;103:54-62.
20. Strauss-Ayali D, Conrad SM, Mosser DM. Monocyte subpopulations and their differentiation patterns during infection. J Leukoc Biol 2007;82:244.
21. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.[see comment]. Arthritis Rheum 1997;40:1725.
22. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-40.
23. Ter Borg EJ, Horst G, Limburg PC, Van Rijswijk MH, Kallenberg CG. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol 1990;17:1642-8.
24. Webster JI, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. Annu Rev Immunol 2002;20:125-63.
25. Agarwal SK, Marshall GD Jr. Glucocorticoid-induced type 1/type 2 cytokine alterations in humans: a model for stress-related immune dysfunction. J Interferon Cytokine Res 1998;18:1059-68.
26. Bianchi M, Meng C, Ivashkiv LB. Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids. Proc Natl Acad Sci U S A 2000;97:9573-8.
27. Gagro A, Tominac M, Krsulovic-Hresic V etal. Increased Toll-like receptor 4 expression in infants with respiratory syncytial virus bronchiolitis. Clin Exp Immunol 2004;135:267-72.
28. Meszaros K, Aberle S, White M, Parent JB. Immunoreactivity and bioactivity of lipopolysaccharide-binding protein in normal and heat-inactivated sera. Infect Immun 1995;63:363-5.
29. Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 2003;55:61-70.
30. Ehrchen J, Steinmuller L, Barczyk K etal. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood 2007;109:1265-74.
31. Trottier MD, Newsted MM, King LE, Fraker PJ. Natural glucocorticoids induce expansion of all developmental stages of murine bone marrow granulocytes without inhibiting function. Proc Natl Acad Sci U S A 2008;105:2028-33.
32. Clark AR. Anti-inflammatory functions of glucocorticoid-induced genes. Mol Cell Endocrinol 2007;275:79-97.
33. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis 2003;3:722-7.
34. Walport MJ. Complement and systemic lupus erythematosus. Arthritis Res 2002;4 (Suppl 3):S279-93.
35. Anolik JH, Aringer M. New treatments for SLE: cell-depleting and anti-cytokine therapies. Baillieres Best Pract Res Clin Rheumatol 2005;19:859-78.
36. Bihl F, Salez L, Beaubier M etal. Overexpression of Toll-like receptor 4 amplifies the host response to lipopolysaccharide and provides a survival advantage in transgenic mice. J Immunol 2003;170:6141-50.
37. Kalis C, Kanzler B, Lembo A, Poltorak A, Galanos C, Freudenberg MA. Toll-like receptor 4 expression levels determine the degree of LPS-susceptibility in mice. Eur J Immunol 2003;33:798-805.
38. Liu B, Yang Y, Dai J etal. TLR4 up-regulation at protein or gene level is pathogenic for lupus-like autoimmune disease. J Immunol 2006;177:6880-8.
39. Migita K, Miyashita T, Maeda Y etal. Toll-like receptor expression in lupus peripheral blood mononuclear cells. J Rheumatol 2007;34:493-500.
40. Komatsuda A, Wakui H, Iwamoto K etal. Up-regulated expression of Toll-like receptors mRNAs in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Clin Exp Immunol 2008;152:482-7.
41. Papadimitraki ED, Choulaki C, Koutala E etal. Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: implications for the induction and maintenance of the autoimmune process. Arthritis Rheum 2006;54:3601-11.
42. Hong Z, Jiang Z, Liangxi W etal. Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. Int Immunopharmacol 2004;4:223-34.
43. Tett SE, Cutler DJ, Day RO, Brown KF. Bioavailability of hydroxychloroquine tablets in healthy volunteers. Br J Clin Pharmacol 1989;27:771-9.
44. Macfarlane DE, Manzel L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol 1998;160:1122-31.
45. Tacke F, Randolph GJ. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 2006;211:609-18.
46. O'Mahony DS, Pham U, Iyer R, Hawn TR, Liles WC. Differential constitutive and cytokine-modulated expression of human Toll-like receptors in primary neutrophils, monocytes, and macrophages. Int J Med Sci 2008;5:1-8.
47. Visintin A, Mazzoni A, Spitzer JH, Wyllie DH, Dower SK, Segal DM. Regulation of Toll-like receptors in human monocytes and dendritic cells. J Immunol 2001;166:249-55.
48. Laakko T, Fraker P. Rapid changes in the lymphopoietic and granulopoietic compartments of the marrow caused by stress levels of corticosterone. Immunology 2002;105:111-9.
49. Hajeer AH, Hutchinson IV. Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum Immunol 2001;62:1191-9.
50. Elahi MM, Asotra K, Matata BM, Mastana SS. Tumour necrosis factor alpha-308 gene locus promoter polymorphism: an analysis of association with health and disease. Biochim Biophys Acta 2009;1792:163-72.
51. Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC. Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 1999;18:17-22.
52. Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 2000;18:565-70.
53. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996;35:1067-74.
54. Roger T, Froidevaux C, Le Roy D etal. Protection from lethal gram-negative bacterial sepsis by targeting Toll-like receptor 4. Proc Natl Acad Sci U S A 2009;106:2348-52.